Related Experiment Video

Updated: Jul 20, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Emerging drugs to replace current leaders in first-line therapy for breast cancer

Michael C Cox1, Tu D Dan, Sandra M Swain

  • 1National Cancer Institute - National Institutes of Health, Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, Bethesda, MD, USA.

Expert Opinion on Emerging Drugs
|August 31, 2006
PubMed

Insights

New breast cancer treatments offer improved efficacy and targeted therapies, addressing drug resistance and side effects. These advancements promise better quality of life for patients with breast cancer.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Growing understanding of breast cancer biology, drug resistance, and side effects necessitates novel therapeutic strategies.
  • Current treatments face limitations, driving the need for more effective and targeted breast cancer medications.

Purpose of the Study:

  • To review emerging therapeutic agents for breast cancer treatment.
  • To highlight advancements in chemotherapy formulations and molecularly targeted therapies.

Main Methods:

  • Literature review of recent studies on novel breast cancer agents.
  • Discussion of specific drug classes including improved paclitaxel and epothilone formulations.
  • Analysis of molecularly targeted agents like bevacizumab, sunitinib malate, pertuzumab, and lapatinib.
  • Inclusion of mTOR inhibitors and farnesyl transferase inhibitors.

Main Results:

  • New agents demonstrate potential to overcome resistance and reduce side effects.
  • Improved formulations of paclitaxel and epothilones offer enhanced efficacy.
  • Molecularly targeted drugs show promise in targeting oncogenic pathways in breast cancer.

Conclusions:

  • Emerging breast cancer therapies represent significant progress in treatment options.
  • These novel agents hold the potential to improve patient quality of life and treatment outcomes.
  • Further research and clinical application of these agents are anticipated to advance breast cancer care.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...